EIP Pharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eippharma.com
A Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 20
- Registration Number
- NCT06815965
- Locations
- 🇫🇷
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg), Strasbourg, France
RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
- Conditions
- Dementia with Lewy Bodies
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 159
- Registration Number
- NCT05869669
- Locations
- 🇺🇸
Houston Methodist Hospital - Stanley Appel Neurology Dept, Houston, Texas, United States
🇺🇸Sana Research, Arlington, Virginia, United States
🇺🇸Center for Cognitive Health, Portland, Oregon, United States
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 91
- Registration Number
- NCT04001517
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸University of California San Diego (UCSD), La Jolla, California, United States
🇺🇸Massachusetts General Hospital, Charlestown, Massachusetts, United States
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 15
- Registration Number
- NCT03980938
- Locations
- 🇬🇧
John Van Geest Centre for Brain Repair, Cambridge, United Kingdom
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 161
- Registration Number
- NCT03402659
- Locations
- 🇺🇸
MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts, United States
🇺🇸Alzheimer's Memory Center and Research Institute, Charlotte, North Carolina, United States
🇨🇿Cerebrovaskulární poradna s.r.o., Moravská Ostrava, Czechia
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 16
- Registration Number
- NCT02423122
- Locations
- 🇳🇱
Alzheimer Research Center, VU Medical Center, Amsterdam, Netherlands
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- EIP Pharma Inc
- Target Recruit Count
- 16
- Registration Number
- NCT02423200
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States